window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Patient Engagement

  • Clinical & Regulatory,Opinion & Events

    Flexibility and precision: How Phastar is driving innovation in clinical trials

    As the pharmaceutical industry marks World Clinical Trials Day 2025, [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    Patient priorities must shape trial design, says One2Treat lead

    To mark Clinical Trials Day, Discover Pharma speaks with Tom [...]

    May 5, 2026
  • Biotech & Pharma Business

    Suvoda and Greenphire finalize merger to integrate trial tech and financial management

    May 5, 2026
  • Clinical & Regulatory

    Teckro launches patient data return feature to enhance transparency and engagement in clinical trials

    May 5, 2026
Previous12

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top